Aktieanalys

InDex Pharmaceuticals: Q3 2022, glimpsing an exciting 2023 - Redeye

{newsItem.title}

Redeye Publicerad: 23 Nov 2022 13:24

Redeye leaves its comments on InDex Pharmaceuticals following its Q3 2022 report. The report did not contain any significant surprises, and the trajectory of the ongoing phase lll-trial CONCLUDE remains the most vital thing for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/865108/index-pharmaceuticals-q3-2022-glimpsing-an-exciting-2023?utm_source=finwire&utm_medium=RSS

Nyheter om Flerie

Läses av andra just nu

Om aktien Flerie

Senaste nytt